Skip to content

Grifols develops and produces essential plasma medicines and other innovative biopharmaceuticals to treat chronic, rare and, at times, life-threatening conditions. The company also provides a comprehensive portfolio of solutions in transfusion medicine while supplying biological materials for research and further manufacturing. In addition, Grifols offers hospitals, pharmacies and healthcare professionals solutions and services that deliver efficient, expert medical care.

Grifols, with more than 27,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

For more information, please visit www.grifols.com

×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.